Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer: Positive, Negative, or a More Complex Issue?

Andrew A Davis^{1

2}, Massimo Cristofanilli^{1

2}

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
² Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.

Editorial

Andrew A Davis et al. JAMA Oncol. 2020.

. 2020 Sep 1;6(9):1332-1333.

doi: 10.1001/jamaoncol.2020.2285.

Andrew A Davis^{1

2}, Massimo Cristofanilli^{1

2}

¹ Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
² Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.

No abstract available

Comment on

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP. Radovich M, et al. JAMA Oncol. 2020 Sep 1;6(9):1410-1415. doi: 10.1001/jamaoncol.2020.2295. JAMA Oncol. 2020. PMID: 32644110 Free PMC article. Clinical Trial.